ProCE Banner Activity

Advances in the Treatment of Pancreatic Cancer: Nursing Education to Optimize Clinical Practice

Watch this on-demand Webcast of a CCO live meeting to gain expert insights on current data and best practices in managing patients with pancreatic cancer.

Released: August 18, 2020

Expiration: August 17, 2021

No longer available for credit.

Share

Faculty

Gayle Jameson

Gayle Jameson, MSN, ACNP-BC, AOCN

Associate Investigator, Nurse Practitioner
Oncology Clinical Trials
HonorHealth Research Institute
Scottsdale, Arizona
Adjunct Faculty
Associate Investigator, Nurse Practitioner

Translational Genomics Research Institute
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Celgene

Learning Objectives

  • Support patient engagement and decision-making through education and communication
  • Explain to patients the current guidelines and clinical findings on individualized therapies for newly diagnosed advanced pancreatic cancer
  • Evaluate treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Discuss the available data and ongoing trials investigating FOLFIRINOX or nab-paclitaxel as neoadjuvant and adjuvant therapy
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer

Faculty Disclosure

Primary Author

Gayle Jameson, MSN, ACNP-BC, AOCN

Associate Investigator, Nurse Practitioner
Oncology Clinical Trials
HonorHealth Research Institute
Scottsdale, Arizona
Adjunct Faculty
Associate Investigator, Nurse Practitioner

Translational Genomics Research Institute
Phoenix, Arizona

Gayle Jameson, MSN, ACNP-BC, AOCN, has disclosed that she has received funds for research support and fees for non-CME/CE services from Celgene.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.